My belief is once we get the Brazil trial up and running that will be the catalyst for a significant uptrend, which will be buoyed by good enrollment numbers, every hundred patients enrolled will put more pressure on the upward movement of the price.
If we get the trial moving with strong enrollment. I think we'll be at least somewhere between $7.00-$8.00 by the end of the year.